Cargando…

Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study

OBJECTIVE: Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richards, Jesse, Bang, Neha, Ratliff, Erin L., Paszkowiak, Maria A., Khorgami, Zhamak, Khalsa, Sahib S., Simmons, W. Kyle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661993/ https://www.ncbi.nlm.nih.gov/pubmed/37990682 http://dx.doi.org/10.1016/j.obpill.2023.100080

Ejemplares similares

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
por: Ozeki, Yoshinori, et al.
Publicado: (2022)

Independent risk factors for amputation in diabetic foot
por: Shojaiefard, Abolfazl, et al.
Publicado: (2008)

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2021)

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
por: Webb, Neil, et al.
Publicado: (2018)

Malignant Schwannoma of Anterior Abdominal Wall: Report of a Case
por: Khorgami, Zhamak, et al.
Publicado: (2009)

The level of impaired esophageal bolus transit measured by multichannel intraluminal impedance: Cross-sectional study
por: Tuma, Faiz, et al.
Publicado: (2021)

Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists
por: Okamoto, Aki, et al.
Publicado: (2021)

Gastrointestinal Interoception in Eating Disorders: Charting a New Path
por: Khalsa, Sahib S., et al.
Publicado: (2022)

Processes and pathways to binge eating: development of an integrated cognitive and behavioural model of binge eating
por: Burton, Amy L., et al.
Publicado: (2019)

THE TOLL OF BINGE EATING ON AGING: THE PHYSICAL FUNCTIONING OF OLDER WOMEN WITH WEEKLY BINGE EATING
por: Hooper, Savannah, et al.
Publicado: (2022)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
por: Overgaard, Rune V., et al.
Publicado: (2018)

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
por: Mahapatra, Manoj K., et al.
Publicado: (2022)

Binge eating and psychostimulant addiction
por: Blanco-Gandia, M Carmen, et al.
Publicado: (2021)

The sequential binge: a new therapeutic approach for binge eating
por: Neveu, Remi, et al.
Publicado: (2015)

Alexithymia and metabolic syndrome: the mediating role of binge eating
por: Conti, Chiara, et al.
Publicado: (2020)

Binge eating behavior in a sample of Lebanese Adolescents: Correlates and Binge Eating Scale validation
por: Mina, Anthony, et al.
Publicado: (2021)

Retention, engagement, and binge‐eating outcomes: Evaluating feasibility of the Binge‐Eating Genetics Initiative study
por: Flatt, Rachael E., et al.
Publicado: (2022)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

Neurofeedback strategies in binge-eating disorder as predictors of EEG-neurofeedback regulation success
por: Wimmer, Jytte, et al.
Publicado: (2023)

Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response?
por: Paszkowiak, Maria, et al.
Publicado: (2023)

Placebo response in binge eating disorder
por: Jacobs-Pilipski, M Joy, et al.
Publicado: (2007)

Improved Planning Abilities in Binge Eating
por: Neveu, Rémi, et al.
Publicado: (2014)

Binge eating symptomatology, BMI, and health
por: Mackenzie, Jennifer, et al.
Publicado: (2015)

Psychofarmacological approach for Binge- eating disorders
por: Muñoz Martinez, V., et al.
Publicado: (2022)

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
por: McLean, Brent A., et al.
Publicado: (2021)

Differences between adolescents exhibiting moderate binging and non-binging eating behaviors
por: Cuzzocrea, Francesca, et al.
Publicado: (2015)

Associations of childhood maltreatment with binge eating and binge drinking in emerging adult women
por: Friedman, J.K., et al.
Publicado: (2023)

Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder
por: Monteleone, Alessio Maria, et al.
Publicado: (2017)

Neuroanatomical Correlates of Binge-Eating Behavior: At the Roots of Unstoppable Eating
por: Oliva, Rossella, et al.
Publicado: (2021)

Adverse childhood experiences and binge-eating disorder in early adolescents
por: Chu, Jonathan, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Health-Related Quality of Life in Obese Presurgery Patients with and without Binge Eating Disorder, and Subdiagnostic Binge Eating Disorders
por: Sandberg, Rita Marie, et al.
Publicado: (2013)

Effect of BMI and Binge Eating on Food Reward and Energy Intake: Further Evidence for a Binge Eating Subtype of Obesity
por: Dalton, Michelle, et al.
Publicado: (2013)

Validation of the Arabic version of the binge eating scale and correlates of binge eating disorder among a sample of the Lebanese population
por: Zeidan, Rouba Karen, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ebq9ch9jbiu6skq9v5vuvvvpc